Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.

Archives of medical research - 1 Jan 2016

Zha Yong, Gan Ping, Liu Qin, Yao Qian

Abstract excerpt

BACKGROUND AND AIMS: The present study analyzed the relationship between TP53 codon 72 polymorphisms and the clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel chemotherapy. METHODS: Three hundred patients with advanced gastric cancer treated with paclitaxel and capecitabine combination chemotherapy were enrolled in the present study. Genomic DNA was extracted from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Genes, p53

Share to Paclitaxel

Share to Pharmacogenetics

Share to Stomach Neoplasms

Source

Identifiers

PMID: 26696550
DOI: 10.1016/j.arcmed.2015.12.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.PMID 26696550Read ↗

TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.Semantic proximity Read ↗

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.Semantic proximity Read ↗

Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer.Semantic proximity Read ↗

p53 Codon 72 Polymorphism and Gastric Cancer Risk in a Chinese Han PopulationSemantic proximity Read ↗

p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population.Semantic proximity Read ↗

Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.Semantic proximity Read ↗

The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients.Semantic proximity Read ↗

P53 codon 72 polymorphism and gastric cancer: A meta‐analysis of the literatureSemantic proximity Read ↗

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.Semantic proximity Read ↗

An updated meta-analysis of the p53 codon 72 polymorphism and gastric cancer risk.Semantic proximity Read ↗

Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma.Semantic proximity Read ↗

Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.